Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 231

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 231
---
 and the company’s competitive positioning.

Negotiations with potential target companies as Tribe Capital Growth Corp I*

Since the IPO, Tribe Capital Growth evaluated and considered several potential target companies operating in sectors such as crypto, health-tech, biosciences, media & communications, supply chain management, online dating, F&B, automotive technology and metaverse as candidates for a possible business combination transaction. The erstwhile management, Tribe Capital, adopted a quantitative bottom-up diligence approach that focuses on product-market fit, growth patterns, unit economics, customer base diversity, market standing in respective sector, operating regions (if they facilitate high growth), track record of management team and technology (proprietary, performance and other such metrics). Tribe Capital Growth and its advisors compiled a list of high priority potential targets and updated and supplemented such list from time to time. Tribe Capital Growth has:

•

Identified and conducted preliminary screening of 65+ potential acquisition target companies;

•

Preliminary screening resulted in 35 companies that could be potential de-SPAC targets based on business model, team background, product scalability and application. Tribe Capital Growth executed non-disclosure agreements with these companies to gather further information on these companies from their dataroom.

•

Upon having an executed non-disclosure agreement in place, Tribe Capital Growth held introductory calls with the management of these companies wherein Tribe Capital Growth obtained an understanding of the respective capital requirements of these companies and understanding on how Tribe Capital Growth could play a role.

•

Following the introductory call with the companies’ management, 19 companies provided dataroom access for Tribe Capital Growth to conduct a deep dive analysis into each of these companies. Tribe Capital Growth conducted its quantitative diligence on these companies including meetings with the senior management of the companies and their respective advisors to assess and review their respective business plans, financial projections and assumptions, their underlying opportunities and risks, historical and expected financial performance, macroeconomic trends impacting the business and operating industry, competitive positioning, track record of the senior management team, the company’s technology and potential impact from trends in the overall economy and industry, regulatory environment and benefits/ challenges related to such company engaging in a potential de-SPAC transaction with Tribe Capital Growth to become a public company.

•

The above analysis resulted in Tribe Capital Growth issuing letters of intents to five potential target companies.

<div align='center'>108</div>

TABLE OF CONTENTS

Target A: On March 10, 2021, Tribe Capital Growth signed a non-disclosure agreement with a technology-enabled healthcare provider that focused on the end-to-end patient